

COT-14

CLINICAL FEATURES OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS

Nayuta Higa¹, Hajime Yonezawa¹, Hiroyuki Uchida¹, Tatsuki Oyoshi¹, Koji Yoshimoto¹; ¹Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

INTRODUCTION: Here, we discuss the presentation, histology, therapy, and outcome of central nervous system tumors in children. **METHODS:** Treatment outcome and management was assessed for children diagnosed with central nervous tumors from 2007 to 2017 at Kagoshima University. **RESULTS:** Eight-eight patients (56 boys, 32 girls) with a mean age of 10.3 years were included in this study. Patient tumor types included: germ cell tumor (n = 26); medulloblastoma (n = 16); pilocytic astrocytoma (n = 8); glioblastoma (n = 8); ependymoma (n = 6, 1 with grade 2, 5 with grade 3); hemangioblastoma, schwannoma, and ganglioglioma (n = 3 each); SEGA, pilomyxoid astrocytoma, and diffuse astrocytoma (n = 2 each), and anaplastic astrocytoma, PPTID, PNET, PXA, DIA, central neurocytoma, astroblastoma, meningioma, and choroid plexus papilloma (n = 1 each). The most common patient clinical features were headache and vomiting associated with hydrocephalus. The median follow-up period was 61 months. All patients with germ cell tumors underwent adjuvant chemotherapy and radiation therapy (RT); patients with germinoma or immature teratoma were still alive, while patients with embryonal carcinoma, yolk sac tumor, or choriocarcinoma had poor prognosis with a median survival of 16 months. For cases of ependymoma, three patients received ICE chemotherapy and RT, and two patients received RT alone; median survival time was 31 months. For high grade glioma, seven patients received temozolomide and RT, and two patients received temozolomide alone; median survival time was 13 months. **CONCLUSIONS:** Patients with germ cell tumors had a relatively good prognosis, while patients with ependymoma or high grade glioma had a poor prognosis. As treatment strategies for ependymoma and high grade glioma are currently limited, it is necessary to evaluate treatment options in consideration of clinical course and quality of life, in addition to histologic and genetic findings.

COT-15

LITERATURE REVIEW ON THE DECISION MAKING OF THE BRAIN TUMOR PATIENT

Tatsuya Kishi¹, Naoya Sakurada¹, Mayumi Horikawa¹, Haruaki Ohkubo¹, Kazumi Ishii¹, Yasuji Miyakita, Makoto Ohno, Masamichi Takahashi, Yoshitaka Narita; ¹National Cancer Center Hospital in Japan Nursing Division Tokyo, Japan

BACKGROUND: Patients with primary brain tumors find it difficult to make decisions during the advanced disease stage and experience decreased consciousness. It is important for patients to receive supported decision-making early. Medical staff should know what to do and when to do it, but there are no clear guidelines. Therefore, we reviewed the literature for supported decision-making for primary brain tumor patients, particularly to provide information for understanding trends reported in previous research. **METHOD:** On January 1, 2019, we conducted a search using keywords, such as "brain tumor" and "decision-making," via PubMed and "Igakuchuo-zashi" in Japan. We extracted literature about treatment decision support and end-of-life care for patients with primary brain tumors. Furthermore, we studied and chose the documents for information provision. **RESULT:** Upon observing 7 studies, we found: 1) about 50% of the patients want more prognostic information; 2) patients with brain tumor tend to be anxious, but they want more information to develop a good understanding of the disease and to lower their anxiety; 3) about half of the brain tumor patients in end-of-life care are unable to make decisions sooner owing to impaired consciousness, and hence are unable to share treatment preferences with their doctors; 4) when medical professionals provide information, such as adding video tools about end-of-life care to oral explanations, it facilitates supported decision-making; and 5) when the caregiver intends to notify patients, the family feels conflicted. **DISCUSSION:** The results suggested that if the timing of the end-of-life conversation is late, it becomes difficult for the patient to make decisions and the burden of decision-making falls on the family. It is necessary to examine effective supported decision-making tools for patients by assessing and comprehending information needs and anxiety levels of primary brain tumor patients.

COT-16

INDICATION OF SYSTEMIC THERAPY FOR ELDER PATIENTS WITH BRAIN TUMORS: A SYSTEMATIC REVIEW AND PERSPECTIVE

Yoko Nakasu¹, Koichi Mitsuya, Satoshi Nakasu, Kazuhiko Nozaki¹; ¹Department of Neurosurgery, Shiga University of Medical Science, Shiga, Japan

BACKGROUND: Little is known about indications and outcome prediction of systemic therapy for elderly patients with brain tumours. Clin-

ical conditions of individuals are heterogeneous from healthy to frail or diseased, moreover, are often reversible. **METHOD:** We retrieved the literature of brain tumour, systemic therapy, chemotherapy, immunotherapy, in randomized controlled trials (RCTs) and reviews on PubMed database from 2008 to 2018. **RESULTS:** 1) Definition of elderly by age in years: Depending on each protocol, the definition is arbitrary. Patients older than 60 or 70 years are usually in the elderly group. 2) Systemic evaluation: Performance status (PS) and visceral function are not sufficient to assess elderly patients. Assessment tools specifically developed for the geriatric population are recommended to evaluate individual patients. 3) Effects and toxicity of systemic therapy: Only a few RCT showed no inferiority of outcome in patients older than 60 or 65 years. There are only few evidences about the senile fragility of blood-brain barrier or distribution of drugs in the elderly brain. Molecular subtyping of brain tumours might predict the effects and toxicities of therapies for elderly patients. **CONCLUSION:** Feasibility of modern systemic therapies are not well studied for elderly patients with brain tumours. Clinical condition varies in individual elderly patients. We need prospective studies of systemic therapy in elderly patients based on an eligibility with not only chronologic age but comprehensive geriatric assessments.

COT-17

EFFECT OF BEVACIZUMAB AGAINST CYSTIC COMPONENT OF PRIMARY/METASTATIC BRAIN TUMORS

Fumiyuki Yamasaki¹, Motoki Takano¹, Ushio Yonezawa¹, Akira Taguchi¹, Shumpei Onishi¹, Kaoru Kurisu¹, Kazuhiko Sugiyama; ¹Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan

BACKGROUND: Bevacizumab (BEV) improves the symptom via reducing the peritumoral edema and sometimes via reducing the size of brain tumor. However, the effect of BEV against cystic part of brain tumor has not been documented yet. In this report, we investigated the effect of BEV on cystic component of brain tumors. **MATERIALS AND METHODS:** Our institutional review board approved this retrospective study. Between 2008 and 2018, 139 patients with primary or metastatic brain tumor were treated with BEV in our Hospital. We defined cystic lesions as high intense lesion of size 1 cm or bigger on T2WI, and excluded necrotizing cysts and cystic changes in surgical resection cavity. The symptoms and images before and after administration of bevacizumab were evaluated. Changes in cyst size of brain tumor was evaluated as follows: CR (complete response=disappearance), PR (reduction by 50% or more), MR (reduction by 25–50%), SD (size change less than 25%), PD (increase by 25% or more). The effect of bevacizumab on tumor itself was determined according to RANO criteria. **RESULTS:** Of the 139 patients, 21 (15.1%) brain tumors had cystic component. The best response of cyst to BEV were as follows: CR 6, PR 7, MR 4, SD 4. The group of patients with progressively increasing cysts prior to BEV administration had significant cyst size reduction compared to stable cyst size groups at best response timing (mean 76.3% vs. 32.8%, $P < 0.01$). Patients with cyst showed significant improvement of symptoms after the treatment with BEV compared to patients without cyst ($P < 0.01$). However, response rate against tumor itself was not different between patients with or without cyst. Overall survival of glioblastoma patients after starting BEV was not different between tumor with cyst and without cyst. **CONCLUSION:** BEV may be effective for patients who are symptomatic due to cystic enlargement.

COT-18

TWO CASES OF GLIOBLASTOMA WITH ASYMPTOMATIC PULMONARY ARTERY EMBOLISM AND DEEP VEIN THROMBOSIS FROM ADMISSION TO HOSPITAL.

Yusuke Kobayashi¹, Takashi Kon¹, Katsuyoshi Shimizu¹, Daisuke Tanioka¹, Yosuke Satou¹, Tohru Mizutani¹; ¹The Department of Neurosurgery, University of Showa, Tokyo, JAPAN

Patients with malignant tumors are susceptible to concurrent venous thromboembolism. We report two cases of glioblastomas that showed asymptomatic pulmonary embolism and deep vein thrombosis on admission. The first case was a 77-year-old male. He was referred to our clinic for a tumor found in the left temporal lobe on computed tomography scan performed when he suffered pneumonia. On admission, he had a Karnofsky performance status (KPS) score of 50 and an elevated D-dimer level (16.46 $\mu\text{g/ml}$). Pulmonary embolism and deep vein thrombosis were noted on detailed examination. Direct oral anticoagulant (DOAC) therapy resulted in the disappearance of pulmonary embolism. On biopsy, the tumor was diagnosed as glioblastoma. The patient underwent radiation therapy in combination with chemotherapy. The second case was a 71-year-old female. She developed a disorder of consciousness and was admitted to a clinic. Brain magnetic resonance imaging (MRI) revealed a high T2 signal area in the left temporal lobe. The patient was initially diagnosed with encephalitis. Though the consciousness disorder improved quickly, she was referred to our clinic after a hyperintense area was observed on MRI. On admission, she